RE:RE:RE:News I agree. In fact, the supplemental patent and all IP developed since the incorporation of ATE might very well be the underlying reason for coming to an arrangemnt. As new products/IP come into play, accruable to ATE, the distinction between what IP can be attributed to each party becomes increasingly blurred. This could impact the royalty payments to AHI for new drugs. Better to resolve these differences amicably in-house rather than in a more open forum later on.
Curious...when I was looking into applicable patents, I came across the reference below, which assigns the listed patents to ATE, and not AHI. Wouldn't it be splendid if Antibe, in anticipation of the amalgamation, arranged to have these patents transferred to itself in advance? Just kidding. LOL
https://patents.justia.com/assignee/antibe-therapeutics-inc